Alok A. Khorana, MD, of the Cleveland Clinic, discusses study findings on rivaroxaban thromboprophylaxis in high-risk ambulatory patients, which showed a reduction in venous thromboembolism and related death (Abstract LBA1).
Gilles A. Salles, MD, PhD, of Centre Hospitalier Lyon Sud, discusses trial findings on the monoclonal antibody MOR208 combined with lenalidomide in people with relapsed or refracto...
Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, discusses trial findings on ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in peop...
John P. Leonard, MD, of Weill Cornell Medicine/Cornell University, discusses phase III findings on lenalidomide plus rituximab vs rituximab plus placebo for people with relapsed or...
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Loretta J. Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, discuss find...
Jennifer Ann Woyach, MD, of The Ohio State University, discusses trial findings on ibrutinib alone or in combination with rituximab compared with bendamustine plus rituximab in unt...
